FOCAL, NCT02318368 / 2014-003443-35: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label |
|
|
| Terminated | 2 | 10 | Europe, US, RoW | Ficlatuzumab, Ficla, Erlotinib, Erlotinib hydrochloride, placebo | AVEO Pharmaceuticals, Inc., Biodesix, Inc. | Non-small Cell Lung Cancer | 01/17 | 01/17 | | |
CyFi2, NCT04100330: A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Withdrawn | 2 | 0 | NA | Ficlatuzumab, AV-299, Cytarabine, Ara-C, Arabinosylcytosine | AVEO Pharmaceuticals, Inc., Biodesix, Inc. | Acute Myeloid Leukemia | 03/20 | 03/20 | | |
P30CA023074, NCT03422536: Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma |
|
|
| Completed | 2 | 78 | US | Cetuximab, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Ficlatuzumab, Anti-HGF Monoclonal Antibody SCH900105, AV-299, SCH 900105 | University of Arizona, National Cancer Institute (NCI) | Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer, Oropharyngeal Cancer, HNSCC, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma | 03/22 | 04/22 | | |
NCT01039948: A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer |
|
|
| Completed | 1b/2 | 203 | RoW | AV-299 + gefitinib, Other name: ficlatuzumab, Formerly SCH 900105, Gefitinib, Iressa® | AVEO Pharmaceuticals, Inc. | Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer, Respiratory Tract Neoplasms | 08/13 | 08/13 | | |
